Inhibitors of tyrosine kinases

Details Inhibitors of tyrosine kinases Inhibitors of tyrosine kinases

2011-06-07

2011-06-07

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252180, C514S275000, C544S122000, C544S295000, C544S331000

Reexamination Certificate

active

07956053

ABSTRACT:
The invention relates to compounds of formulawherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.

REFERENCES:
patent: 4788195 (1988-11-01), Torley et al.
patent: 5516775 (1996-05-01), Zimmermann et al.
patent: 5521184 (1996-05-01), Zimmermann
patent: 7169791 (2007-01-01), Breitenstein et al.
patent: 7569566 (2009-08-01), Breitenstein et al.
patent: 2006/0014742 (2006-01-01), Asaki et al.
patent: 0 588 762 (1994-03-01), None
patent: 6-184116 (1994-07-01), None
patent: 8-4110140 (2004-01-01), None
patent: 95/09853 (1995-04-01), None
patent: 00/62778 (2000-10-01), None
patent: 02/46170 (2002-06-01), None
patent: 02/46171 (2002-06-01), None
patent: 2004/002963 (2004-01-01), None
Zimmermann et al., “Potent and Selective Inhibitors of the ABL-Kinase: Phenylamino-Pyrimidine (PAP) Derivatives,” Bioorganic & Medical Chemistry Letters, vol. 7, No. 2, pp. 187-192 (1997).
Zimmermann et al., “Phenylamino-Pyrimidine (PAP)—Derivatives: A New Class of Potent and Highly Selective PDGF-Receptor Autophosphorylatin Inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 11, pp. 1221-1226 (1996).
Paul et al., “Preparation of Substituted N-Phenyl-4-aryl-2-pyrimidinamines as Mediator Release Inhibitors,” J. Med. Chem., vol. 36, pp. 2716-2725 (1993).
Bhat et al., “Interactions of CBL with BCR-ABL and CRKL in BCR-ABL transformed Myeloid Cells,” The Journal of Biological Chemistry, vol. 272, No. 26, Issue of Jun. 27, pp. 16170-16175 (1997).
Shibuya et al., “Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to thefmsfamily,” Oncogene, vol. 5, pp. 519-524 (1990).
Dorsey et al., “Discovery of a Novel ABL Tyrosine Kinase Inhibitor That Selectively Induces Apoptosis of BCR-ABL-Positive Leukemic Cells,” Abstracts/Hematology, vol. 28(7), Suppl. 1, p. 49 (2000).
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010 (1996).
Traxler, “Protein tyrosine kinase inhibitors in cancer treatment,” Exp. Opin. Ther. Patents, 7(6):571-588 (1997).
Druker et al: “Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia”, New England Journal of Medicine, 355 (23), pp. 2408-2417, Dec. 7, 2006.
Kantarjian Hagop M, et al: “Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance”, Blood, 110(10, pp. 3540-3546, Nov. 2007.
European Public Assessment Report (EPAR) “TASIGNA” EPAR summary for the public, European medicines Agency, EMEA/h?c/798, Oct. 2007.
O'Hare Thomas et al: “In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants”, Cancer Research, 2005; 65:(11), Jun. 1, 2005, pp. 4500-4505.
Coleman James P, et al: “Synthesis and characterization of novel analogs of conjugated bile acids containing reversed amide bond”, Journal of Lipid Research, vol. 36, pp. 901-910, 1995.
Coleman J P, et al: “Metabolic fate and hepatocyte toxicity of reverse amide analogs of conjugated ursodexycholate in the rat”, Steroid Biochem. Molec. Biol. vol. 64 (1/2), pp. 91-101, 1998.
Lesieur D. et al: “Design and strucure activity relationships of naphthalenic ligands of the melatonin receptors”, Proceedings, XIVth International Synposium on Medicinal Chemistry 1997 Elsevier Science B.V., pp. 231-239.
EMEA, Tasigna, Scientif Discussion 2007, pp. 1/52-4/52.

Affiliated with

Also associated with

Rating

Inhibitors of tyrosine kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of tyrosine kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of tyrosine kinases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2646579